Forex
World
Market
Business
Cryptocurrency
Commodities
MAP
Publish for free
Business
financetom
/
Business
/
--Okta Guides For Q2 EPS of $0.60-$0.61 on Revenue of $631-$633 Million, vs CIQ Analyst Consensus of $0.54/Share on Revenue of $617 Million
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
Forex
Stocks Market
Commodities
--Okta Guides For Q2 EPS of $0.60-$0.61 on Revenue of $631-$633 Million, vs CIQ Analyst Consensus of $0.54/Share on Revenue of $617 Million
May 29, 2024 1:31 PM
04:03 PM EDT, 05/29/2024 (MT Newswires) --
Price: 90.00, Change: -6.36, Percent Change: -6.60
Previous page:
Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve
Next page:
Analysis-Nestle CEO Freixe's turnaround plan faces challenge from weak consumer
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Release time ⇩
Release time ⇧
Like count ⇩
Show More Comments
Related Articles >
Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve
Oct 18, 2024
08:48 AM EDT, 10/18/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Friday that its Arcutis Canada subsidiary has received regulatory approval from Health Canada for Zoryve topical foam 0.3% to treat seborrheic dermatitis in patients aged 9 and older. The approval was based on data from a phase 3 study, along with findings from a phase 2 study,...
Analysis-Nestle CEO Freixe's turnaround plan faces challenge from weak consumer
Oct 18, 2024
LONDON (Reuters) - Nestle's plans under new CEO Laurent Freixe to restructure and sharpen its focus on its top brands were welcomed by investors, but executing a turnaround strategy against a backdrop of weak consumer demand will be a tough task. After replacing Mark Schneider as CEO last month, Freixe set out plans on Thursday to revamp the executive board,...
Gilead voluntarily withdraws urothelial cancer drug in US
Oct 18, 2024
Oct 18 (Reuters) - Gilead Sciences ( GILD ) said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator. (Reporting by Sneha S K) ...
Activist investor Jana Partners builds about 5% stake in Lamb Weston, WSJ reports
Oct 18, 2024
Oct 18 (Reuters) - Activist investor Jana Partners has built a stake of about 5% in frozen fries supplier Lamb Weston ( LW ) , the Wall Street Journal reported on Friday, citing people familiar with the matter. ...
About
Terms and Conditions
Privacy policy
Cookie Settings
Contact Us
Services
Login
register
financetom
Market
Personal Finance
Business
Economy
Cryptocurrency
MAP
Links
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
Copyright 2023-2026 -
www.financetom.com
All Rights Reserved
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
MAP